COMPANY NEWS


Zydus Lifesciences Ltd
BSE Code 532321 ISIN Demat INE010B01027 Book Value (₹) 145.11 NSE Symbol ZYDUSLIFE Div & Yield % 0.61 Market Cap ( Cr.) 99,939.16 P/E * 37.18 EPS * 26.71 Face Value (₹) 1
* Profit to Earning Ratio
* Earning Per Share
Zydus receives USFDA tentative approval for Letermovir tablets Back
(23 Mar 2024)
Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) to market Letermovir tablets, 240 mg and 480 mg, (USRLD: Prevymis® tablets).

Letermovir tablets are used to prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received a bone marrow transplant or kidney transplant. The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India. Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24).